12:00 AM
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HGT1410: Phase I/II data

Top-line data from an open-label, European Phase I/II trial in about 12 patients with Sanfilippo A syndrome showed that once-monthly 10, 45 and 90 mg doses of intrathecal HGT1410 were well tolerated...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >